Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Bitcoin

In This Story HIMS -9.34% NVO +1.21% BAC +0.68% Hims & Hers ( HIMS -9.34% ), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry. Suggested Reading Meta doesn't want you to read this book. So of course it's a best-seller Nvidia and GM are partnering to build self-driving cars Chinese EV makers are having a moment Bitcoin will be $200,000 by 2026, Anthony Scaramucci says CC Share